Interagency Patent Coordination and Improvement Act of 2025 establishes a task force between the USPTO and FDA to share information and provide.
The Interagency Patent Coordination and Improvement Act of 2025 establishes an interagency task force between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) to coordinate efforts regarding patents, particularly for human drugs and biological products. The task force will share information, provide technical assistance, and establish protocols to safeguard confidentiality. The Director of the USPTO and the Commissioner of the FDA must consult with each other through this task force.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.